Novo Nordisk agreed to acquire global rights to Omeros’ MASP‑3–blocking antibody zaltenibart for up to $2.1 billion plus sales royalties, paying roughly $340 million up front and near‑term milestones. Novo plans pivotal testing in paroxysmal nocturnal hemoglobinuria (PNH) and other complement‑mediated rare diseases, citing potential advantages over existing complement inhibitors. The deal repositions Omeros’ asset within a major rare‑disease franchise and gives Novo a new complement‑modulating approach. Blockade of MASP‑3 targets a distinct node in the complement cascade; companies will watch Phase 3 results to assess differentiation versus approved complement drugs and next‑generation candidates.